IONS250117P45000
- 8.90
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment
Express News | FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in Sma
S&P 500 Futures Climb In Premarket Trading; Tempus AI, IDACORP Lead
Ionis Pharmaceuticals Insider Sold Shares Worth $1,091,444, According to a Recent SEC Filing
Insider Sale: EVP Research of $IONS (IONS) Sells 7,154 Shares
Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock With Biggest Upside Potential
Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51
Ionis Pharmaceuticals (IONS) Gets a Hold From Bernstein
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
Ionis Pharmaceuticals Analyst Ratings
RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70
RBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $67
Wells Fargo Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Ionis Pharmaceuticals: Strategic Path to Cash Flow Positivity and Strong Pipeline Drive Buy Rating
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $55
Ionis Pharmaceuticals: Hold Rating Amid Uncertainty in Future Financial Performance
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Ionis to Present at 43rd Annual J.P. Morgan Healthcare Conference
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected